Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

AbbVie's Veliparib Fails in Two Phase III Cancer Combination Therapy Studies

AbbVie’s investigational oral poly(ADP-ribose) polymerase (PARP) inhibitor veliparib failed in two Phase III combination therapy trials in patients with ...

Forward this item to a colleague:


(Separate multiple addresses by commas)